. . . "0"^^ . . "2008-03-05+01:00"^^ . "kidney transplantation; immunosuppressive drugs; gene polymorphism; pharmacogenetics; cyclosporine; tacrolimus"@en . . . "1"^^ . "3"^^ . "ABCB1/MDR1 halotypes modify the risk of acute rejection and MDR1 ABCB1 allelic arrangement is a stronger regulator of P-glycoprotein. CYP3A haplotypes control the bioavailability of tacrolimus, but do not modify the risk of acute rejection."@en . "0"^^ . " pharmacogenetics" . . "3"^^ . "Variabilita gen\u016F ovliv\u0148uj\u00EDc\u00ED biologickou dostupnost imunosupresiv a jej\u00ED vztah ke kr\u00E1tkodob\u00FDm i dlouhodob\u00FDm v\u00FDsledk\u016Fm transplantace ledviny" . "The influence of gene variability on the bioavailability of immunosuppressiv drugs and its relation to the short-term and long-term outcome of kidney transplantation"@en . "2011-04-27+02:00"^^ . "Observation of the influence of polymorphisms in CYP3A4, CYP3A5 and MDR-1 genes on the metabolism of immunosuppressive drugs in kidney transplant recipients. Observation of effect of polymorphisms in CYP3A4, CYP3A5 and MDR-1 genes on the occurrence of early acute rejection and long-term complications after kidney transplantation."@en . "NR8816" . . . . " gene polymorphism" . . . . . . "http://www.isvav.cz/projectDetail.do?rowId=NR8816"^^ . " cyclosporine" . . "Sledov\u00E1n\u00ED vlivu polymorfismu gen\u016F pro CYP3A4, CYP3A5 a MDR-1 na metabolismus a vst\u0159eb\u00E1v\u00E1n\u00ED imunosupresiv a jejich souvislost s \u00FAsp\u011B\u0161nost\u00ED imunosupresivn\u00ED l\u00E9\u010Dby. Sledov\u00E1n\u00ED vlivu polymorfismu gen\u016F pro CYP3A4, CYP3A5 a MDR-1 na vznik \u010Dasn\u00E9 akutn\u00ED rejekce a dlouhodob\u00E9 komplikace po transplantaci ledviny." . . "2008-12-31+01:00"^^ . "kidney transplantation" . . "2006-01-01+01:00"^^ . " immunosuppressive drugs" . "Haplotypov\u00E9 uspo\u0159\u00E1d\u00E1n\u00ED ABCB1/MDR1 genu modifikuje riziko vzniku akutn\u00ED rejekce a rozlo\u017Een\u00ED alel je siln\u011Bj\u0161\u00EDm regul\u00E1torem aktivity P-glykoproteinu. Halotypy CYP3A kontroluj\u00ED biologickou dostupnost takrolimu, ale neovlyv\u0148uj\u00ED riziko akutn\u00ED rejekce."@cs . .